Cefotetan
As of the edition of 20 October 2026, Cefotetan is a small molecule: marketed, first approved in 1985 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1985
- Kind
- Small molecule
- Brand name
- Cefotan
- First approved
- 27 December 1985 (US)
- Approvals on record
- 7 in 1 region
- Holder of the most recent approval
- B. Braun Medical; 2 holders in all
- Registered trials
- 4, 0 stopped early
- Disease areas
- Infections; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Stuart Therapeutics | Earlier holder | 1985 to now |
| AstraZeneca | Later holder | 1993 to now |
| B. Braun Medical | Later holder | 2007 to now |
| Pharmaceutical Associates | Acquired holder | 2022 to now |